Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nondepleting Antibody Therapy Reverses Diabetes Symptoms in Mouse Model

By LabMedica International staff writers
Posted on 16 Jul 2012
A mouse diabetes model was treated by an immunotherapeutic approach based on novel nondepleting antibodies specific for the T-cell receptors CD4 and CD8.

Residual beta cells found at the time of the clinical onset of type I diabetes are sufficient to control hyperglycemia, if they can be rescued from ongoing autoimmune destruction. More...
To achieve this end, investigators at the University of North Carolina (Chapel Hill, NC, USA) developed an immunotherapeutic approach based on antibodies specific for the CD4 and CD8 receptors found on "autoreactive" T-cells. They then used these antibodies to treat members of a population of the mouse NOD diabetes model.

They reported in the June 29, 2012, online edition of the journal Diabetes that a short course of treatment with nondepleting antibodies specific for the CD4 and CD8 coreceptors rapidly reversed clinical disease in recent-onset diabetic NOD mice. Blood sugar levels returned to normal within 48 hours of treatment. Within five days, about 80% percent of the treated animals had entered diabetes remission with reversal of clinical symptoms.

Once established, remission was maintained indefinitely while immunity to foreign antigens was unimpaired. Induction of remission involved selective T-cell purging of the pancreas and draining pancreatic lymph nodes and upregulation of transforming growth factor (TGF)-beta1 by pancreas-resident antigen-presenting cells. Neutralization of TGF-beta1 blocked the induction of the remission process. In contrast, maintenance of remission was associated with tissue-specific immunoregulatory T cells.

"The protective effect is very rapid, and once established, is long-term," said senior author Dr. Roland Tisch, professor of microbiology and immunology at the University of North Carolina. "We followed the animals in excess of 400 days after the two antibody treatments, and the majority remained free of diabetes. And although the antibodies are cleared from within the animals in two to three weeks after treatment, the protective effect persists."

"We have demonstrated that the use of nondepleting antibodies is very robust," said Dr. Tisch. "We are now generating and plan to test antibodies that are specific for the human version of the CD4 and CD8 molecules."

Related Links:

University of North Carolina School



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.